



Assistant Professor Xin Zhang

**Faculty/Department:**

Faculty of Medicine - School of Pharmacy, Macau University of Science and Technology; State Key Laboratory of Quality Research in Chinese Medicine

**Email Address:** [xinzhang@must.edu.mo](mailto:xinzhang@must.edu.mo)

**Phone Number:** ( 853 ) 63260979

**Office:** E213b

**Address:** Avenida Wai Long, Taipa, Macau, China

**Research Areas:**

Tumor pathogenesis, inpatient drug monitoring, adverse drug reactions, observation of clinical efficacy of drugs, analysis of current status of clinical application of drugs, pharmacogenetic testing

**Teaching Areas:**

Epidemiology, pharmacology and toxicology, hospital pharmacy, anatomy and physiology laboratory, biochemistry and molecular biology laboratory, medical ethics, pharmacy and health care

**Academic Qualifications:**

2017.06 PhD in Epidemiology and Statistics, School of Public Health, Jilin University

2009.07 Master of Science in Cardiovascular Pharmacology, School of Pharmacy, Jilin University

2006.07 B.S. in Pharmacy, School of Pharmacy, Jilin University

**Work Experience:**

2022.07~Present Assistant Professor, Faculty of Medicine, School of Pharmacy, Macau University of Science and Technology

2020.09~2022.06 Lecturer, School of Pharmacy, Macau University of Science and Technology

2011.05~2012.10 The First Hospital of Jilin University, Phase I Drug Clinical Trial Research Laboratory

2009.08~2020.09 Clinical Pharmacist, Lead Teacher, Associate Chief Pharmacist, The First Hospital of Jilin University

**Scientific Research:**

1. Macau Science and Technology Development Fund: establishment of in vivo drug sensitivity detection platform based on MiniPDX animal tumor model and screening of small molecule inhibitors of lung cancer (2023-2026). 2,209,000.00MOP, PI.

2. National Key R&D Program of Ministry of Science and Technology: Prevention, Control and Intervention Strategies for Cardiovascular Damage of Anti-tumor Drugs (2023-2026). 7,000,000.00RMB, co-I.

3. Macau Science and Technology Development Fund: Study on ZYZ-802 of garlic source for the treatment of papillary thyroid cancer and its mechanism of action (2021-2023). 710,000.00MOP, PI.

4. The research fund of Macau University of Science and Technology (MUST) : ZYZ-802 on the prevention of chemically induced multi-organ tumorigenesis in SD rats (2022-2023). 100,000.00 MOP, PI.

5. The National Natural Science Foundation of China (NSFC) Young Scientists Fund Project:

Study on the relationship between miRNAs specifically binding to FOXE13'UTR single nucleotide polymorphic sites and the risk level of papillary thyroid cancer (2017-2019).

170,000.00 RMB, PI.

**Articles Publication(selected):**

1. Discovery of deoxyandrographolide and its novel effect on vascular senescence by targeting HDAC1. Lin Z, He H, Xian Y, Cai J, Ge Q, Guo M, Zheng Q, Liu X, Mo C, **Zhang X**, Qi W, Zhang Y, Liang L, Yu XY, Zhu YZ. *MedComm* . 2023,4(5):e338.
2. The mirrored cationic peptide as miRNA vehicle for efficient lung cancer therapy. Xu W, Du L, Yu L, Cen H, Lin F, Wang S, Ruan Z, Lin Z, **Zhang X**, Zhou N, Chang J, Yu X, Zhang L, Liang L. *MedComm* . 2023,4(4):e273.
3. MiR-204-5p-targeted AP1S2 is necessary for papillary thyroid carcinoma. Gu Y, **Zhang X**, Li Y, Shi J, Cui H, Ren Y, Liu S, Qiao Y, Cheng Y, Liu Y. *Mol Cell Endocrinol*. 2023,20(574):111993.
4. Inhibition of YAP1 activity ameliorates acute lung injury through promotion of M2 macrophage polarization. Liang L, Xu W, Shen A, Fu X, Cen H, Wang S, Lin Z, Zhang L, Lin F, **Zhang X**, Zhou N, Chang J, Chen ZS, Li C, Yu X. *MedComm* . 2023,4(3):e293.
5. Tianjiao Wang, **Xin Zhang**, Na Zhou, et al. Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose – Response Meta-Analysis of Randomized Controlled Trials. *J Am Heart Assoc*. 2023,12:e029512.
6. Nitric oxide and thyroid carcinoma: A review. Huang Y, Suguro R, Hu W, Zheng J, Liu Y, Guan M, Zhou N, **Zhang X\***. *Front Endocrinol (Lausanne)*. 2023,9(13):1050656.
7. Identification of proline, 1-pyrroline-5-carboxylate and glutamic acid as biomarkers of depression reflecting brain metabolism using carboxylomics, a new metabolomics method. Bian X, Zhou N, Zhao Y, Fang Y, Li N, **Zhang X**, Wang X, Li Y, Wu JL, Zhou T. *Psychiatry Clin Neurosci*. 2023,77(4):196-204.
8. Yu Huang, **Xin Zhang\***, Na Zhou. The Interrelation between Interleukin-2 and Schizophrenia. *Brain Sci*. 2022,12(9):1154.
9. **Xin Zhang**, Jennifer A Ritonja, Na Zhou, et al. Omega-3 Polyunsaturated Fatty Acids Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials. *Am Heart Assoc*. 2022,7(11): e025071.

10. **Xin Zhang**, Yulu Gu, Yong Li, et al. Association of rs944289, rs965513, and rs1443434 in TITF1/TITF2 with risks of papillary thyroid carcinoma and with nodular goiter in northern Chinese Han populations. *Int J Endocrinol.* 2020, 11:4539747.
11. Na Zhou, **Xin Zhang**, Jia-Qing Yan, et al. Prevalence of Oral Mucosal Diseases in Older Adults in Mainland China: A Meta-Analysis of Observational Studies. *IJ ERPH.* 2020, 17, 1887.
12. Ziwei Wang, Na Zhou, Jianqi Zhao, **Xin Zhang\***. Sodium azulene sulfonate reverses multidrug resistance in K562/A02 cells. *Cellular and Molecular Biology.* 2019, 65(7):105-110.
13. Wang Ziwei, Zhou Na, Fang Shengbo, **Zhang Xin\***. Effect of ursolic acid on obesity-induced insulin resistance in rat liver. *Tropical Journal of Pharmaceutical Research.* 2018, 17(5): 837-842.
14. Gu Y, Shi J, Qiu S, Qiao Y, **Zhang X**, et al. Association between ATM rs1801516 polymorphism and cancer susceptibility: a meta-analysis involving 12,879 cases and 18,054 controls. *BMC Cancer.* 2018, 18(1):1060.